Elephas is a live tumor imaging diagnostics company focused on enhancing cancer treatment through personalized therapy determination. The company leverages advancements in cancer biology, multimodal microscopy, engineering, and artificial intelligence to analyze human live tumor fragments. This innovative platform aims to improve clinical decision-making for oncologists, enabling them to tailor treatments to individual patients. Additionally, Elephas seeks to accelerate drug development processes, addressing the urgent need for effective cancer therapies in a rapidly evolving healthcare landscape.
Orbital Therapeutics is focused on advancing global health through the development of RNA-based medicines aimed at treating various human diseases. The company is building an innovative platform that integrates established and emerging technologies, delivery mechanisms, and data analytics to create a diverse portfolio of therapeutics. Their efforts encompass a wide range of applications, including vaccines, immunomodulation, protein replacement, and regenerative medicine. By harnessing the full potential of RNA technology, Orbital Therapeutics seeks to provide patients with modern treatment options that were previously unavailable, thus enhancing the efficacy and accessibility of medical therapies.
Vizgen, Inc. is a biotechnology company that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. The company's flagship technology, MERFISH, utilizes multiplexed single-molecule imaging to accurately measure the quantity and spatial distribution of RNA within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various applications, including oncology, immunology, neuroscience, infectious disease, and regenerative medicine. Established in 2019 and based in Cambridge, Massachusetts, Vizgen is committed to advancing research by enabling high-throughput and cost-effective analysis of complex biological systems at a cellular level.
Proof Diagnostics focuses on developing CRISPR-based molecular tests for the detection of COVID-19. The company aims to empower communities by providing rapid diagnostic kits that enable medical professionals to effectively test patients for coronavirus infections. By leveraging advanced genetic technologies, Proof Diagnostics contributes to improved health outcomes and better management of infectious diseases.
Developer of digital health platform designed for employers, providers, and managed care organizations. The company's software offers different tools, education, and guidance through digital and virtual data with the help of health assessments, and message-based and video interactions with professionals, enabling the healthcare industry to empower patients to actively engage in their health no matter their location or circumstance.
hC Bioscience is an innovator and pioneer of protein editing using context agnostic engineered tRNA. Their First in Class approach for protein editing advances beyond genome editing to direct modification of the proteome.
Oxford NanoImaging Limited specializes in the development and manufacture of advanced microscopy tools for life sciences research. The company's flagship product, the Nanoimager, is a single-molecule fluorescence microscope designed to detect biomolecules, including disease-related protein markers and pathogens, at single copy numbers. This innovative microscope features capabilities such as 3D imaging and dual-color super-resolution, enhancing researchers' ability to study complex biological processes. In addition to the Nanoimager, Oxford NanoImaging offers various microscopy technologies, including Förster Resonance Energy Transfer microscopy, direct stochastic optical reconstruction microscopy, and photoactivated localization microscopy. Founded in 2016 and headquartered in London, with an additional office in Menlo Park, California, the company aims to make life science tools and knowledge accessible to a wider audience.
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.
Developer of digital health platform designed for employers, providers, and managed care organizations. The company's software offers different tools, education, and guidance through digital and virtual data with the help of health assessments, and message-based and video interactions with professionals, enabling the healthcare industry to empower patients to actively engage in their health no matter their location or circumstance.
ImmuneID is a precision immunology company that has developed a proprietary platform aimed at identifying and therapeutically targeting antibody interactions involved in immune diseases. The platform utilizes advanced methodologies, including massively parallel, multiplexed, and unbiased systems, to facilitate the development of therapeutics for various conditions such as autoimmunity, severe allergies, oncology, and infectious diseases. By enabling researchers to observe and analyze human immune responses across different stages of disease progression, ImmuneID seeks to enhance the understanding of immune mechanisms and improve treatment strategies.
Interline Therapeutics is a drug discovery platform based in South San Francisco, California, founded in 2020 by Zach Sweeney. The company specializes in mapping and correcting dysfunctional protein communities to elucidate the molecular mechanisms of disease. By utilizing advancements in genomics, proteomics, structural biology, and computational chemistry, Interline aims to develop a precision medicine approach that focuses on three key areas: genomics, communities, and modulators. This innovative methodology enables the identification of new medicines targeting genetically validated signaling pathways and ensures that drug candidates effectively address dysfunctional disease networks. Through collaborations with leading academic institutions, Interline Therapeutics strives to enhance drug discovery and improve therapeutic outcomes.
Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in manufacturing reagents for tissue imaging and multiplexing detection, primarily serving the life science and biomedical research communities. Ultivue offers advanced technologies such as DNA-PAINT and DNA-Exchange, which facilitate the collection of high-resolution microscopic images. These innovations are aimed at enhancing the understanding of biological processes and medical diagnostics. The company’s products are designed for use in fluorescent microscopy-based research and are expected to have future applications in clinical diagnostics.
Vizgen, Inc. is a biotechnology company that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. The company's flagship technology, MERFISH, utilizes multiplexed single-molecule imaging to accurately measure the quantity and spatial distribution of RNA within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various applications, including oncology, immunology, neuroscience, infectious disease, and regenerative medicine. Established in 2019 and based in Cambridge, Massachusetts, Vizgen is committed to advancing research by enabling high-throughput and cost-effective analysis of complex biological systems at a cellular level.
Interline Therapeutics is a drug discovery platform based in South San Francisco, California, founded in 2020 by Zach Sweeney. The company specializes in mapping and correcting dysfunctional protein communities to elucidate the molecular mechanisms of disease. By utilizing advancements in genomics, proteomics, structural biology, and computational chemistry, Interline aims to develop a precision medicine approach that focuses on three key areas: genomics, communities, and modulators. This innovative methodology enables the identification of new medicines targeting genetically validated signaling pathways and ensures that drug candidates effectively address dysfunctional disease networks. Through collaborations with leading academic institutions, Interline Therapeutics strives to enhance drug discovery and improve therapeutic outcomes.
ImmuneID is a precision immunology company that has developed a proprietary platform aimed at identifying and therapeutically targeting antibody interactions involved in immune diseases. The platform utilizes advanced methodologies, including massively parallel, multiplexed, and unbiased systems, to facilitate the development of therapeutics for various conditions such as autoimmunity, severe allergies, oncology, and infectious diseases. By enabling researchers to observe and analyze human immune responses across different stages of disease progression, ImmuneID seeks to enhance the understanding of immune mechanisms and improve treatment strategies.
Altos Labs is a biotechnology company dedicated to cellular rejuvenation programming aimed at restoring cell health and resilience. This innovative approach seeks to reverse diseases and transform medical practices. The company brings together a diverse community of leading scientists, clinicians, and industry experts who collaborate to advance this mission. Altos Labs operates in the San Francisco Bay Area and San Diego, as well as in Cambridge, UK, and maintains significant research collaborations in Japan.
Walden Biosciences, Inc, a biotechnology company, develops medicines for individuals living with kidney disease. It targets suPAR, an inflammatory biomarker that connects the kidney to the innate immune system; and Dynamin, a complex enzyme that rebuilds podocytes and the base structure of the kidney. The company was incorporated in 2013 and is based in Cambridge, Massachusetts.
Dewpoint Therapeutics, Inc. is a Boston-based biotechnology company focused on the research and development of biomolecular condensates to create innovative treatments for a range of diseases, including cancer, neurodegenerative disorders, immunology, cardiovascular issues, women's health, and virology. Founded in 2018, the company utilizes a proprietary, AI-powered drug discovery platform that employs machine learning and advanced image analysis to visualize and manipulate biomolecular condensates. This technology aids in identifying novel drug candidates and has applications across various therapeutic areas. Dewpoint Therapeutics collaborates with leading academic and pharmaceutical partners to enhance its research and development efforts, aiming to deliver impactful healthcare solutions.
Singleron Biotechnologies is a developer and provider of clinical diagnosis, health management and drug development products and services. The company is dedicated to applying single cell analysis techniques and has obtained a world wide exclusive IP license from Yale University for its uniquely designed microfluidic single cell processing device, and has developed the innovative SCOPE single-cell pre-sequencing preparation system based on this microfluidic device.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
Mindstrong Inc., operating as Mindstrong Health, focuses on remote patient monitoring and mental health symptom assessment through its innovative application. The platform utilizes AI-powered digital biomarker technology to enable users to monitor their mental health symptoms continuously and objectively. Mindstrong offers a range of services, including cognitive behavioral therapy, crisis management, and psychoeducation, delivered through structured messaging sessions. The company develops comprehensive care pathways that integrate passively collected data on cognitive function and mood, enhancing patient engagement through telehealth solutions. Founded in 2013 and based in Mountain View, California, Mindstrong collaborates with various stakeholders, including pharmaceutical companies, healthcare providers, and academic institutions, to advance medical innovation and improve healthcare delivery.
Vizgen, Inc. is a biotechnology company that specializes in developing advanced spatially resolved transcriptomic profiling tools aimed at enhancing understanding of biological systems related to human health and disease. The company's flagship technology, MERFISH, utilizes multiplexed single-molecule imaging to accurately measure the quantity and spatial distribution of RNA within individual cells. This innovative approach facilitates single-cell gene expression profiling in intact tissue slices, providing valuable insights into various applications, including oncology, immunology, neuroscience, infectious disease, and regenerative medicine. Established in 2019 and based in Cambridge, Massachusetts, Vizgen is committed to advancing research by enabling high-throughput and cost-effective analysis of complex biological systems at a cellular level.
Omniome, Inc. is a biotechnology company based in San Diego, California, established in 2013. It specializes in developing a proprietary DNA sequencing platform that aims to deliver high accuracy in sequencing results. The company employs its Sequencing By Binding technology, which enhances nucleotide and DNA matching by utilizing the natural matching capabilities of polymerase. This innovative approach not only provides precise and rapid results but also offers a cost-effective solution, which has the potential to significantly advance cancer diagnostics. Omniome is backed by prominent life sciences venture investors and is focused on becoming a trusted leader in the field of clinical sequencing.
Cardero Therapeutics is a start-up pharmaceutical company that is developing a novel class of therapeutics that induces the formation of new mitochondria (mitochondrial biogenesis) and enhances mitochondrial function in response to metabolic demand. Chronic depletion of mitochondria, the principal source of cellular ATP, has been directly linked to the progression of heart failure, sarcopenia, and neurodegeneration. Cardero Therapeutics is collaborating with numerous academic medical centers to advance novel drug candidates structurally based on a newly discovered human hormone that appears to fundamentally regulate mitochondrial density and function in all tissues. Cardero Therapeutics believes that enhancing myocyte bioenergetics will comprise an innovative therapeutic approach complementary to currently available cardiovascular drugs. The company’s clinical development focus is the lethal cardiomyopathy associated with orphan diseases characterized by loss of mitochondria in muscle and heart, resulting in heart failure that is poorly responsive to current medical interventions. Initial clinical trials are directed toward Duchenne muscular dystrophy and Friedreich’s ataxia.
Feelmore Labs is an innovative health & wellness technology company. We are a health and wellness tech company based in New York City , developing a new category of medical & consumer devices that improves how you feel.
One BioMed Pte. Ltd., incorporated in 2015 and based in Singapore, specializes in integrated molecular diagnostics services. The company has developed a diagnostics testing platform that facilitates the purification and isolation of nucleic acids from various samples. This platform incorporates proprietary silicon biophotonics sensing technology, allowing for the efficient detection of infectious diseases at the point of care. Through its innovative approach, One BioMed aims to enhance diagnostic capabilities for healthcare providers.
Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in manufacturing reagents for tissue imaging and multiplexing detection, primarily serving the life science and biomedical research communities. Ultivue offers advanced technologies such as DNA-PAINT and DNA-Exchange, which facilitate the collection of high-resolution microscopic images. These innovations are aimed at enhancing the understanding of biological processes and medical diagnostics. The company’s products are designed for use in fluorescent microscopy-based research and are expected to have future applications in clinical diagnostics.
LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.
LunaPBC, Inc. operates a community-owned platform focused on health and DNA research. The company offers LunaDNA, a database that facilitates the sharing of health and genetic data for medical research. This platform supports health research initiatives by both non-profit and for-profit organizations, contributing to medical discoveries. LunaPBC operates as a Public Benefit Corporation, emphasizing community welfare by allowing individuals to share their health data, which in turn drives research and innovation. Additionally, members of the platform have the opportunity to share in the earnings derived from medical advancements, promoting a sense of shared ownership and benefit within the community. Founded in 2017 and based in San Diego, California, LunaPBC aims to advance genomic and medical research while prioritizing the interests of its contributors.
Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.
Glympse Bio, Inc. is focused on developing innovative diagnostic solutions that facilitate noninvasive monitoring of various diseases, including cancer, fibrosis, immunological disorders, and infectious diseases. The company employs modular nanoparticle sensors, utilizing precisely engineered diagnostic agents that assess disease states within the body and convey this information through urine analysis. This approach allows for predictive monitoring and evaluation of treatment responses. Founded in 2015 and based in Cambridge, Massachusetts, Glympse Bio's technology is rooted in research originally conducted at MIT and led by a team of experts in nanomedicine and biomedical engineering. Their flagship product, Glympse Inside, serves as a comprehensive platform for disease monitoring and aims to revolutionize how diseases are diagnosed and managed.
Omniome, Inc. is a biotechnology company based in San Diego, California, established in 2013. It specializes in developing a proprietary DNA sequencing platform that aims to deliver high accuracy in sequencing results. The company employs its Sequencing By Binding technology, which enhances nucleotide and DNA matching by utilizing the natural matching capabilities of polymerase. This innovative approach not only provides precise and rapid results but also offers a cost-effective solution, which has the potential to significantly advance cancer diagnostics. Omniome is backed by prominent life sciences venture investors and is focused on becoming a trusted leader in the field of clinical sequencing.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Mindstrong Inc., operating as Mindstrong Health, focuses on remote patient monitoring and mental health symptom assessment through its innovative application. The platform utilizes AI-powered digital biomarker technology to enable users to monitor their mental health symptoms continuously and objectively. Mindstrong offers a range of services, including cognitive behavioral therapy, crisis management, and psychoeducation, delivered through structured messaging sessions. The company develops comprehensive care pathways that integrate passively collected data on cognitive function and mood, enhancing patient engagement through telehealth solutions. Founded in 2013 and based in Mountain View, California, Mindstrong collaborates with various stakeholders, including pharmaceutical companies, healthcare providers, and academic institutions, to advance medical innovation and improve healthcare delivery.
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
LunaDNA is a community-owned platform that facilitates the sharing of health and DNA data for medical research. Founded by the creators of Illumina, a leader in DNA sequencing, LunaDNA addresses the issue of siloed genomic data by providing individuals with a compelling incentive to share their health information. Participants are rewarded with shares in the database, allowing them to benefit from the profits generated by medical research and discoveries. This model not only empowers users to contribute their health records, genomic data, and personal health experiences but also fosters a sense of community ownership. As researchers pay to access the data for their studies, the proceeds are distributed back to the community, akin to dividends. By prioritizing privacy and trust, LunaDNA aims to increase participation in genomic research while facilitating advancements in healthcare that can ultimately save lives.
Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in manufacturing reagents for tissue imaging and multiplexing detection, primarily serving the life science and biomedical research communities. Ultivue offers advanced technologies such as DNA-PAINT and DNA-Exchange, which facilitate the collection of high-resolution microscopic images. These innovations are aimed at enhancing the understanding of biological processes and medical diagnostics. The company’s products are designed for use in fluorescent microscopy-based research and are expected to have future applications in clinical diagnostics.
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
AnchorDx is a company focused on advancing precision medicine through its development of next-generation sequencing techniques, particularly utilizing molecular liquid biopsies. This approach offers non-invasive access to genetic information, enabling patients to gain insights into their physiological conditions and prepare for potential future health issues. With a core team boasting over 20 years of experience in cancer genomics, genetics, and bioinformatics, AnchorDx aims to establish itself as a leading global provider of precision medical solutions. The company collaborates with various middle and downstream enterprises, fostering a comprehensive industrial chain that spans from academic research to clinical product transformation. Additionally, AnchorDx has formed partnerships with numerous large-scale third-party inspection agencies, hospitals, and research institutes, contributing to the development of independent intellectual property rights and competitive clinical testing products that deliver accurate and comprehensive services to patients, doctors, and medical institutions.
Mindstrong Inc., operating as Mindstrong Health, focuses on remote patient monitoring and mental health symptom assessment through its innovative application. The platform utilizes AI-powered digital biomarker technology to enable users to monitor their mental health symptoms continuously and objectively. Mindstrong offers a range of services, including cognitive behavioral therapy, crisis management, and psychoeducation, delivered through structured messaging sessions. The company develops comprehensive care pathways that integrate passively collected data on cognitive function and mood, enhancing patient engagement through telehealth solutions. Founded in 2013 and based in Mountain View, California, Mindstrong collaborates with various stakeholders, including pharmaceutical companies, healthcare providers, and academic institutions, to advance medical innovation and improve healthcare delivery.
Arbor Biotechnologies operator of a bio-discovery company intended to provide human diagnostic development service. The company's platform employs a diverse set of technologies and techniques including artificial intelligence, genome sequencing, gene synthesis and high-throughput screening, enabling drug developers to accelerate the discovery of proteins for improving human health and sustainability.
908 Devices Inc. is a Boston-based company that develops and sells advanced measurement devices for chemical and biochemical analysis, utilizing mass spectrometry technology. The company's product lineup includes handheld and desktop devices designed for immediate, on-site analysis across various fields such as life sciences, bioprocessing, industrial biotechnology, and forensics. Notable products include the MX908, a portable mass spectrometry device for rapid analysis of unknown substances, the Rebel desktop analyzer for real-time monitoring of bioprocess environments, and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. Established in 2012, 908 Devices aims to make mass spectrometry accessible beyond traditional laboratories, providing reliable tools for professionals needing quick and actionable insights. The company operates mainly in the United States while also serving markets in Europe, Asia, and beyond.
Grail, Inc. is a healthcare company dedicated to developing innovative technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, the company has created Galleri, a blood test designed for asymptomatic individuals over 50 years old, which identifies various types of cancer at early stages. In addition to Galleri, Grail is developing a diagnostic aid called DAC to accelerate the diagnostic process for patients with a clinical suspicion of cancer. The company is also working on tests for minimal residual disease and other post-diagnostic applications. Through high-intensity sequencing and population-scale clinical trials, Grail aims to advance the field of cancer screening and improve patient outcomes.
Vividion Therapeutics, Inc. is a biotechnology company based in San Diego, California, focused on developing therapeutics to address significant unmet medical needs. The company utilizes a novel platform for proteome-wide small molecule drug discovery, which combines proteomic techniques and synthetic chemistry to enhance drug selectivity and broaden the range of druggable proteins. Originating from research at The Scripps Research Institute, Vividion's technology enables the creation of detailed drug interaction maps, facilitating simultaneous target engagement and comprehensive selectivity profiling. By advancing its innovative synthetic and proteomic chemistry approaches, Vividion aims to deliver transformative treatments for patients with serious illnesses.
Nohla Therapeutics' singular passion is the development of best-in-class ex vivo expanded universal donor cellular therapies to transform the treatment of patients with cancer and other life threatening illnesses. Our products are manufactured and cryopreserved on an ongoing basis allowing for a bank of doses that are available for immediate (on demand) use. This is tremendously advantageous with regards to the ease and timing of treatment, the ability to provide repeated dosing for immune-oncology indications and reduction in patient risk and cost relative to other cell therapies.
Genomics Medicine Ireland is a life sciences company focused on conducting extensive research studies throughout Ireland to explore the connections between the human genome, health, and disease. By analyzing genetic information, the company aims to deepen the understanding of how genetics influences various health outcomes and disease susceptibility. Through its research initiatives, Genomics Medicine Ireland seeks to contribute valuable insights that could inform future medical practices and enhance healthcare delivery.
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.
Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.
Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.
Quanterix Corporation is a life sciences company focused on developing an advanced platform for single-molecule analysis, known for its ultra-sensitive digital immunoassay technology. This innovative approach enables precise detection and quantification of individual proteins and small molecules in complex biological samples, which is critical for clinical diagnostics, drug development, and life science research. Quanterix's flagship technology, Simoa, allows for the reliable measurement of protein biomarkers in extremely low concentrations, surpassing conventional immunoassay methods. The company offers a range of products, including assay kits, specialized assays for neurodegenerative diseases, and advanced instrumentation designed to enhance early disease detection and improve patient outcomes. Founded in 2007, Quanterix is supported by prominent life science investors, positioning it to address significant unmet medical needs and contribute to advancements in healthcare.
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Grail, Inc. is a healthcare company dedicated to developing innovative technologies for early cancer detection. Founded in 2015 and based in Menlo Park, California, the company has created Galleri, a blood test designed for asymptomatic individuals over 50 years old, which identifies various types of cancer at early stages. In addition to Galleri, Grail is developing a diagnostic aid called DAC to accelerate the diagnostic process for patients with a clinical suspicion of cancer. The company is also working on tests for minimal residual disease and other post-diagnostic applications. Through high-intensity sequencing and population-scale clinical trials, Grail aims to advance the field of cancer screening and improve patient outcomes.
Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.
Ultivue, Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2015. The company specializes in manufacturing reagents for tissue imaging and multiplexing detection, primarily serving the life science and biomedical research communities. Ultivue offers advanced technologies such as DNA-PAINT and DNA-Exchange, which facilitate the collection of high-resolution microscopic images. These innovations are aimed at enhancing the understanding of biological processes and medical diagnostics. The company’s products are designed for use in fluorescent microscopy-based research and are expected to have future applications in clinical diagnostics.
Arivale Inc. provides wellness services to individuals. It offers individuals with a scientific path to optimize wellness and avoid diseases. The company’s services engages in analyzing various areas of an individual body, such as genome, blood and saliva, gut microbiome, and lifestyle, as well as provides them with actionable recommendations on optimizing their wellness. In addition, it guides individuals on various types of food and exercise that works with their body. Arivale Inc. was incorporated in 2013 and is headquartered in Seattle, Washington.
Denali Therapeutics is a biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151, which are in various phases of clinical trials for Parkinson's disease. Additionally, Denali is developing DNL747, a selective RIPK1 inhibitor currently in Phase 1b trials for Alzheimer's and ALS. It also has programs focused on enzyme replacement therapy for MPS II and antibody transport vehicles targeting key proteins involved in neurodegeneration. Denali collaborates with various organizations, including Takeda Pharmaceutical Company and Genentech, to enhance its research efforts. Founded in 2013, Denali Therapeutics emphasizes a science-driven approach to address the complex challenges posed by neurodegenerative diseases, leveraging recent scientific insights and translational medicine tools.
908 Devices Inc. is a Boston-based company that develops and sells advanced measurement devices for chemical and biochemical analysis, utilizing mass spectrometry technology. The company's product lineup includes handheld and desktop devices designed for immediate, on-site analysis across various fields such as life sciences, bioprocessing, industrial biotechnology, and forensics. Notable products include the MX908, a portable mass spectrometry device for rapid analysis of unknown substances, the Rebel desktop analyzer for real-time monitoring of bioprocess environments, and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. Established in 2012, 908 Devices aims to make mass spectrometry accessible beyond traditional laboratories, providing reliable tools for professionals needing quick and actionable insights. The company operates mainly in the United States while also serving markets in Europe, Asia, and beyond.
Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.
Bellerophon Therapeutics LLC is a clinical stage biotherapeutics company focused on developing innovative therapies at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary and cardiac diseases. Two of the company's product candidates are based on its proprietary pulsatile nitric oxide delivery device, INOpulse®, and are in Phase 2 clinical trials – one for the treatment of PAH and a second for the treatment of PH-COPD. The company's third product candidate, bioabsorbable cardiac matrix (BCM), is an injectable device currently undergoing a feasibility clinical trial, which is a CE mark registration trial in the European Union and is comparable to a Phase 2 trial in U.S. drug development, for the prevention of cardiac remodeling and subsequent congestive heart failure following acute myocardial infarction (heart attack).
NextCODE Health LLC is a clinical diagnostics company specializing in sequence-based genomics. It offers a platform that assists healthcare professionals in obtaining clinical insights for rapid disease diagnosis. The company provides a range of services, including data analysis, genome interpretation, data mining, and sequencing services, both clinical and non-clinical. Founded on technology developed at deCODE genetics over 16 years, NextCODE focuses on integrating genome sequence data into patient care. Based in Cambridge, Massachusetts, the company was acquired by WuXi PharmaTech in 2015 and underwent a rebranding to Genuity Science in 2020. Through its innovative solutions, NextCODE aims to enhance the speed and accuracy of identifying genetic causes of diseases.
Genuity Science is a contract genomics and data-sourcing organization based in Boston, Massachusetts, with additional offices in Dublin, Ireland, and Reykjavik, Iceland. The company collaborates with global biopharma firms to provide comprehensive discovery services that enhance precision health and improve patient outcomes. Its offerings encompass population-scale, disease-specific data sourcing, high-quality sequencing, and advanced statistical analysis, along with software tools for managing large datasets and artificial intelligence applications. Genuity operates state-of-the-art CAP/CLIA genomics laboratories in Woburn, Massachusetts, and Dublin, emphasizing a strong commitment to data stewardship and governance. The company focuses on exploring biological data insights, storage, interpretation, and scalable analytics, particularly in the central nervous system, cardiometabolic, and inflammatory disease sectors.
Boreal Genomics Inc. is a biotechnology company that focuses on the development and commercialization of technologies for blood-based detection and monitoring of circulating tumor DNA. Founded in 2007 and headquartered in Los Altos, California, with an additional office in Vancouver, Canada, the company offers products like OnTarget, which allows for the sensitive detection and quantification of tumor mutations in plasma or tissue. Boreal's platform is designed to enable healthcare professionals to perform accurate genomic profiling and monitor tumor evolution from cell-free DNA in plasma, thereby improving cancer patient care. The OnTarget assay, available as a research-use service, reveals tumor mutations that may be undetectable by other methods, assisting in therapy selection, enhancing clinical trial efficiency, and expediting drug development. Additionally, Boreal provides DNA enrichment and library construction solutions tailored for high accuracy sequencing in liquid biopsy applications.
908 Devices Inc. is a Boston-based company that develops and sells advanced measurement devices for chemical and biochemical analysis, utilizing mass spectrometry technology. The company's product lineup includes handheld and desktop devices designed for immediate, on-site analysis across various fields such as life sciences, bioprocessing, industrial biotechnology, and forensics. Notable products include the MX908, a portable mass spectrometry device for rapid analysis of unknown substances, the Rebel desktop analyzer for real-time monitoring of bioprocess environments, and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. Established in 2012, 908 Devices aims to make mass spectrometry accessible beyond traditional laboratories, providing reliable tools for professionals needing quick and actionable insights. The company operates mainly in the United States while also serving markets in Europe, Asia, and beyond.
Quanterix Corporation is a life sciences company focused on developing an advanced platform for single-molecule analysis, known for its ultra-sensitive digital immunoassay technology. This innovative approach enables precise detection and quantification of individual proteins and small molecules in complex biological samples, which is critical for clinical diagnostics, drug development, and life science research. Quanterix's flagship technology, Simoa, allows for the reliable measurement of protein biomarkers in extremely low concentrations, surpassing conventional immunoassay methods. The company offers a range of products, including assay kits, specialized assays for neurodegenerative diseases, and advanced instrumentation designed to enhance early disease detection and improve patient outcomes. Founded in 2007, Quanterix is supported by prominent life science investors, positioning it to address significant unmet medical needs and contribute to advancements in healthcare.
908 Devices Inc. is a Boston-based company that develops and sells advanced measurement devices for chemical and biochemical analysis, utilizing mass spectrometry technology. The company's product lineup includes handheld and desktop devices designed for immediate, on-site analysis across various fields such as life sciences, bioprocessing, industrial biotechnology, and forensics. Notable products include the MX908, a portable mass spectrometry device for rapid analysis of unknown substances, the Rebel desktop analyzer for real-time monitoring of bioprocess environments, and the ZipChip, a high-resolution separation platform that enhances mass spectrometry sample analysis. Established in 2012, 908 Devices aims to make mass spectrometry accessible beyond traditional laboratories, providing reliable tools for professionals needing quick and actionable insights. The company operates mainly in the United States while also serving markets in Europe, Asia, and beyond.
Hua Medicine is a clinical-stage, innovative drug development company in China, focused on novel therapies for the treatment of diabetes and CNS disorders. Founded by pharma industry veterans and funded by a premier group of international VC investment firms such as Fidelity Asia, Fidelity Biosciences, ARCH Ventures, Venrock, SAIL and WuXi Ventures, the company has in-licensed from major pharma, world-wide rights to a potential best-in-class, oral drug for the treatment of Type 2 Diabetes which utilizes a novel mechanism of action.
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.
Surface Logix is a drug development company specializing in the creation of small molecule drugs aimed at treating metabolic and cardiovascular diseases. Leveraging expertise in biophysical chemistry, the company develops new chemical entities that target specific tissues and organ systems, including the gastrointestinal and cardiovascular systems. Surface Logix focuses on enhancing pharmacokinetic and pharmacodynamic properties of its drugs, striving to offer significant improvements over existing therapies in these therapeutic areas. The company has multiple programs addressing various diseases, showcasing its commitment to advancing treatment options for patients.
Quanterix Corporation is a life sciences company focused on developing an advanced platform for single-molecule analysis, known for its ultra-sensitive digital immunoassay technology. This innovative approach enables precise detection and quantification of individual proteins and small molecules in complex biological samples, which is critical for clinical diagnostics, drug development, and life science research. Quanterix's flagship technology, Simoa, allows for the reliable measurement of protein biomarkers in extremely low concentrations, surpassing conventional immunoassay methods. The company offers a range of products, including assay kits, specialized assays for neurodegenerative diseases, and advanced instrumentation designed to enhance early disease detection and improve patient outcomes. Founded in 2007, Quanterix is supported by prominent life science investors, positioning it to address significant unmet medical needs and contribute to advancements in healthcare.
BIND Therapeutics is a clinical-stage nanomedicine platform company focused on developing targeted and programmable therapeutics known as Accurins. These innovative therapeutics are engineered with specific physical and chemical properties to effectively target particular cells or tissues, allowing for the concentration of therapeutic agents at disease sites. This approach aims to enhance treatment efficacy while reducing adverse effects on healthy tissues. BIND Therapeutics primarily concentrates on oncology, with its lead drug candidate, BIND-014, currently undergoing Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. The company also collaborates with biopharmaceutical firms to develop Accurins utilizing therapeutic payloads from their pipelines. Its operations extend to the United States and Russia, focusing on targeting tumors at tissue, cellular, and molecular levels.
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Surface Logix is a drug development company specializing in the creation of small molecule drugs aimed at treating metabolic and cardiovascular diseases. Leveraging expertise in biophysical chemistry, the company develops new chemical entities that target specific tissues and organ systems, including the gastrointestinal and cardiovascular systems. Surface Logix focuses on enhancing pharmacokinetic and pharmacodynamic properties of its drugs, striving to offer significant improvements over existing therapies in these therapeutic areas. The company has multiple programs addressing various diseases, showcasing its commitment to advancing treatment options for patients.
Ahura Scientific Inc. specializes in developing portable, ultra-compact optical systems designed for the immediate identification and authentication of liquid and solid chemical substances. The company’s handheld Raman spectrometers are particularly utilized for raw material identification and finished product authentication within the pharmaceutical and consumer health sectors. Additionally, its products serve critical functions in the identification of chemicals and explosives, material verification, anti-counterfeiting measures, and medical devices. Manufactured in the USA in an ISO 9001-certified facility, Ahura Scientific's offerings are recognized for their exceptional portability and performance, catering to a diverse clientele that includes agencies and companies across the homeland security, life sciences, industrial, and medical markets.
Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.
Surface Logix is a drug development company specializing in the creation of small molecule drugs aimed at treating metabolic and cardiovascular diseases. Leveraging expertise in biophysical chemistry, the company develops new chemical entities that target specific tissues and organ systems, including the gastrointestinal and cardiovascular systems. Surface Logix focuses on enhancing pharmacokinetic and pharmacodynamic properties of its drugs, striving to offer significant improvements over existing therapies in these therapeutic areas. The company has multiple programs addressing various diseases, showcasing its commitment to advancing treatment options for patients.
The mission of Integrated Diagnostics is to leverage powerful emerging technologies in the development of diagnostic products that enable physicians and patients to manage complex and important diseases such as cancer, diabetes and Alzheimer's through blood tests that can monitor tens to hundreds of disease markers simultaneously. The company plans to develop a pipeline of game-changing diagnostic products that enable the diagnosis and prognosis of a variety of diseases. The company is based on the concept of a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes and other molecules.
Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.
Ahura Scientific Inc. specializes in developing portable, ultra-compact optical systems designed for the immediate identification and authentication of liquid and solid chemical substances. The company’s handheld Raman spectrometers are particularly utilized for raw material identification and finished product authentication within the pharmaceutical and consumer health sectors. Additionally, its products serve critical functions in the identification of chemicals and explosives, material verification, anti-counterfeiting measures, and medical devices. Manufactured in the USA in an ISO 9001-certified facility, Ahura Scientific's offerings are recognized for their exceptional portability and performance, catering to a diverse clientele that includes agencies and companies across the homeland security, life sciences, industrial, and medical markets.
Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.
Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.
Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.
Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.
Surface Logix is a drug development company specializing in the creation of small molecule drugs aimed at treating metabolic and cardiovascular diseases. Leveraging expertise in biophysical chemistry, the company develops new chemical entities that target specific tissues and organ systems, including the gastrointestinal and cardiovascular systems. Surface Logix focuses on enhancing pharmacokinetic and pharmacodynamic properties of its drugs, striving to offer significant improvements over existing therapies in these therapeutic areas. The company has multiple programs addressing various diseases, showcasing its commitment to advancing treatment options for patients.
NexCura specializes in online decision support services tailored for patient communities, offering applications and custom services through an application service provider model. The company's platforms facilitate the collection of comprehensive clinical data, enhancing communication between patients and their physicians. It provides valuable resources such as patient education and market research services. Additionally, NexCura's NexProfiler tools assist in pre-treatment decision-making by integrating clinical evidence with personal concerns and the unique clinical circumstances of individual patients. This aggregated data serves to benefit healthcare organizations, pharmaceutical companies, physicians, and patients alike.
Ahura Scientific Inc. specializes in developing portable, ultra-compact optical systems designed for the immediate identification and authentication of liquid and solid chemical substances. The company’s handheld Raman spectrometers are particularly utilized for raw material identification and finished product authentication within the pharmaceutical and consumer health sectors. Additionally, its products serve critical functions in the identification of chemicals and explosives, material verification, anti-counterfeiting measures, and medical devices. Manufactured in the USA in an ISO 9001-certified facility, Ahura Scientific's offerings are recognized for their exceptional portability and performance, catering to a diverse clientele that includes agencies and companies across the homeland security, life sciences, industrial, and medical markets.
R2 Technology develops and commercializes computer-aided detection systems for the early-detection of breast cancer. R2 Technology pioneered the use of CAD for mammography in 1998 when the ImageChecker system became the first CAD system approved by the FDA for screening mammography. The company was founded in 1993 and is headquartered in Santa Clara, California. As of July 13, 2006, R2 Technology, Inc. operates as a subsidiary of Hologic Inc.
Amphora Discovery Corporation is a biotechnology company based in Durham, North Carolina, focused on providing integrated services to the pharmaceutical and biopharmaceutical industries. Founded in 2001, the company specializes in pathway-based drug discovery and offers a range of services, including in vitro assay protocols, high-throughput screening, compound profiling, custom assay development, and enzymology services. Amphora Discovery's lead generation platform is designed to deliver high precision, selectivity, and data quality, aiding in the development of proprietary clinical entities for various therapeutic areas, including oncology, inflammation, metabolic diseases, and neurological disorders. Notably, the company has advanced preclinical candidates targeting AKT1 and p38, which are specific inhibitors with potential applications in treating cancer and inflammatory conditions. As of 2008, Amphora operates as a subsidiary of Nanosyn Inc.
Illumina is a leading company in the field of genomics, specializing in tools and services for analyzing genetic material with applications in life sciences and clinical laboratories. Founded in 1998 in San Diego, California, by David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel, Illumina primarily generates its revenue from sequencing instruments, consumables, and associated services, accounting for over 90% of its sales. The company’s high-throughput technology facilitates whole genome sequencing in humans and other organisms, while its lower throughput tools are designed for specific applications such as viral and cancer tumor screening. Additionally, Illumina offers microarrays for cost-effective genetic screening, which are used mainly in consumer and agricultural contexts. Through initiatives like Illumina Accelerator, the company fosters innovation by supporting startups with mentorship and access to essential resources, thereby contributing to advancements in personalized medicine and improving human health.
NexCura specializes in online decision support services tailored for patient communities, offering applications and custom services through an application service provider model. The company's platforms facilitate the collection of comprehensive clinical data, enhancing communication between patients and their physicians. It provides valuable resources such as patient education and market research services. Additionally, NexCura's NexProfiler tools assist in pre-treatment decision-making by integrating clinical evidence with personal concerns and the unique clinical circumstances of individual patients. This aggregated data serves to benefit healthcare organizations, pharmaceutical companies, physicians, and patients alike.
Eichrom Europe SAS, based in Bruz, France, specializes in analytical testing services, focusing on the measurement of radioactivity, chemical compounds, and asbestos in radioactive or potentially radioactive samples. Founded in 2003, the company serves various sectors, including decommissioning and dismantling, environmental monitoring of nuclear sites, drinking water testing, radioprotection, and food safety. Eichrom Europe SAS provides comprehensive testing solutions for clients in the nuclear industry, positioning itself as a one-stop shop for radioactivity and asbestos analyses. As of April 2018, it operates as a subsidiary of Eurofins Scientific SE.